Scholarlink

Background <p>Cardiovascular disease (CVD) is recognized as the leading cause of death in patients with systemic lupus erythematosus (SLE). Although the pathways involved in accelerated cardiovascular disease are not yet fully understood, atherogenesis may be dramatically influenced by immune dysregulation in SLE. Evaluating the role of neuropilin-1 (NRP-1) biomarker in early detection of subclinical cardiovascular affection, and as an indicator of disease activity in SLE patients was the aim of this work.</p> Results <p>We evaluated serum human Neuropilin-1&#xa0;(NRP-1) in SLE patients, and controls. We found that&#xa0;serum NRP-1 levels were significantly elevated in SLE patients, particularly in cases of high disease activity, and in those with subclinical cardiovascular affection. About 33% of SLE patients had increased carotid-intimal-medial thikness (CIMT), while 14% had abnormal brachial artery vasodilation response. Regarding SLE instances independent risk factors for subclinical cardiovascular affection included SLE disease activity, duration, body mass index (BMI), systolic and diastolic blood pressure, and serum NRP-1 level.</p> Conclusion <p>Human neuropilin-1 biomarker may represent a potential marker for early detection and prediction of subclinical cardiovascular affection in SLE patients at precise and sensitive cutoff point. In addition to its direct relationship to SLE disease activity; thus; it may serve as an advantageous serological indicator for the prediction of SLE disease activity.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Human neuropilin-1 biomarker as predictor of subclinical cardiovascular affection in systemic lupus erythematosus patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年2月10日

查看全文
  • Samar Gaber Soliman,
  • Samah Samy Yossef,
  • Shaimaa R. Shahin,
  • Dina Mamdoh Serag,
  • Dalia S. Saif

摘要

Background

Cardiovascular disease (CVD) is recognized as the leading cause of death in patients with systemic lupus erythematosus (SLE). Although the pathways involved in accelerated cardiovascular disease are not yet fully understood, atherogenesis may be dramatically influenced by immune dysregulation in SLE. Evaluating the role of neuropilin-1 (NRP-1) biomarker in early detection of subclinical cardiovascular affection, and as an indicator of disease activity in SLE patients was the aim of this work.

Results

We evaluated serum human Neuropilin-1 (NRP-1) in SLE patients, and controls. We found that serum NRP-1 levels were significantly elevated in SLE patients, particularly in cases of high disease activity, and in those with subclinical cardiovascular affection. About 33% of SLE patients had increased carotid-intimal-medial thikness (CIMT), while 14% had abnormal brachial artery vasodilation response. Regarding SLE instances independent risk factors for subclinical cardiovascular affection included SLE disease activity, duration, body mass index (BMI), systolic and diastolic blood pressure, and serum NRP-1 level.

Conclusion

Human neuropilin-1 biomarker may represent a potential marker for early detection and prediction of subclinical cardiovascular affection in SLE patients at precise and sensitive cutoff point. In addition to its direct relationship to SLE disease activity; thus; it may serve as an advantageous serological indicator for the prediction of SLE disease activity.